Latest News and Events
Filter by
Selections
August 8, 2024
Arrowhead Pharmaceuticals Announces $500 Million Strategic Financing Facility with Sixth Street
Read MoreJuly 29, 2024
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Read MoreJune 25, 2024
Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial
Read MoreJune 24, 2024
Arrowhead Pharmaceuticals Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE
Read MoreJune 3, 2024
Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome
Read MoreMay 29, 2024
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia
Read MoreMay 28, 2024